Chemotherapy for patients with hormone-refractory prostate cancer

Annals of Oncology

Volumn 15, Issue 11, 2004, Pages 1582-1584

  Joly, F ^a   Tannock, Ian F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ATRESENTAN; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CLODRONIC ACID; CORTICOSTEROID; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ESTROGEN; FLUTAMIDE; GEFITINIB; GLUCOCORTICOID; GROWTH FACTOR RECEPTOR; HYDROCORTISONE; KETOCONAZOLE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALOPECIA; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TOLERABILITY; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; LOW DRUG DOSE; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE III; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; TAXOIDS; VINBLASTINE;

EID: 9444261998     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh445     Document Type: Editorial

References (20)

1. Murphy GP, Slack NH. Response criteria for the prostate of the USA National Prostatic Cancer Project. Prostate 1980; 1: 375-382.
2. Eisenberger MA, Simon R, O'Dwyer PJ et al. A reevaluation of non-hormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 1985; 3: 827-841.
3. Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3: 1013-1021.
4. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461-3467.
5. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-1764.
6. Fossa SD, Slee PH, Brausi M et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European Organization for Research and Treatment of Cancer genitourinary group. J Clin Oncol 2001; 19: 62-71.
7. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
8. Ernst DS, Tannock IF, Winquist EW et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. J Clin Oncol 2003; 21: 3335-3342.
9. Berry W, Dakhil S, Modiano M et al. Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. J Urol 2002; 168: 2439-2443.
10. Tannock IF, De Wit R, Berry WR et al. A randomized comparison of weekly or three-weekly docetaxel plus prednisone with mitoxantrone plus prednisone for advanced hormone-refractory prostate cancer. N Engl J Med 2004; In press.
11. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine versus mitoxantrone and prednisone for metastatic androgen-independent prostate cancer: results of Southwest Oncology Intergroup Protocol 99-16. N Engl J Med 2004; In press.
12. Abratt RP, Brune D, Meletios-Athanassios D et al. Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 2004; 15: 1613-1621.
13. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
14. Saad F, Gleason DM, Murray R et al. Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
15. Canil CM, Tannock IF. Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone? J Natl Cancer Inst 2002; 94: 1422-1423.
16. Smith MR, Eastham J, Gleason DM et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169: 2008-2012.
17. Shulman MJ, Benaim EA. The natural history of androgen independent prostate cancer. J Urol 2004; 172: 141-145.
18. Small EJ, Halabi S, Dawson NA et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-1033.
19. Beer TM, Eilers KM, Garzotto M et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol 2003; 21: 123-128.
20. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: An Update. Semin Oncol 2004; 31 (Suppl 4): 26-32.